CytomX shifts towards EpCAM
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
ASH 2024 – Merck treads a fine line in ROR1
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
